The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. North America dominates the market while Asia Pacific shows the fastest growth.

Law firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. The stock fell 19% on the news, dropping from $6.31 to $5.13 per share on May 11, 2026.

Law firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effective July 14, 2026. Investors who purchased Certara securities and experienced losses are encouraged to contact the firm.

The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.

The Schall Law Firm announced an investigation into Certara, Inc. (NASDAQ: CERT) for potential securities law violations following the company's May 11, 2026 Q1 earnings report. Certara disclosed declining services revenues and bookings, attributing the weakness to softer performance from Tier 1 customers in MIDD services. The stock fell 19% on the announcement, prompting the law firm to seek shareholders who suffered losses.

Law firm Kirby McInerney LLP is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings report, which revealed a 4% decline in services revenue and 14% decline in services bookings, along with softer Tier 1 customer performance and exit from the regulatory business. The stock price fell 19% on the news.

The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.

The clinical trial software market is expected to grow from $1.32 billion in 2025 to $2.53 billion by 2030, with a CAGR of 13.8%. Growth drivers include increased digitization, adoption of AI and cloud-based solutions, virtual and decentralized trials, and enhanced data security focus. Major players are innovating with unified trial solutions and strategic acquisitions to strengthen their market positions.

Certara announced the sale of its Regulatory and Medical Writing business to Veristat for up to $135 million. The divestiture is expected to close in Q2 2026 and will allow the company to focus on its Model-Informed Drug Development platform. Analysts view this as strategically positive timing, with William Blair noting it removes an overhang and provides capital for reinvestment in core biosimulation platforms.

Kopion Asset Management purchased 327,064 additional shares of Certara (worth ~$3.37 million) during Q4, despite the stock falling 23% post-earnings. The fund views the sharp decline as a buying opportunity, noting that Certara's underlying business remains solid with 10% revenue growth and improved profitability, making it an attractive entry point for disciplined investors.

Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.

The global In Silico Clinical Trials Market is projected to grow from $3.42 billion in 2023 to $6.68 billion by 2032, driven by AI-based modeling, regulatory support, and accelerated drug development strategies.